Global Life Science Business Partnering (GLSBP) - June 2025

Highlights of Deals in June – 2025

 

Happy 4th of July to all our American friends.

Acquisitions

1.     Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of $3 billion(INR 25,689 crore).

2.     KKR-backed IVI to buy ART Fertility Clinics for US$450 million.

3.     Emcure Pharma to acquire remaining 20.42% stake in Zuventus Healthcare for US$86.8 million(INR 724.9 cr.).

4.     Zydus Enters Global Biologics CDMO Market with Acquisition of Agenus' US Manufacturing Facilities.

5.     AbbVie to buy Capstan for up to US$2.1 billion in immunology push.

6.     Lilly pumps Cardio plans with acquisition of gene-editing biotech Verve Therapeutics for US$1.3 billion.

7.     BioNTech to acquire CureVac in US$1.25 billion all-stock deal.

 

Licensing

1.     Bharat Biotech licenses GSK's Shigella under trial vaccine.

2.     Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler.

3.     Novo signs US$812 million weight-loss drug license deal with US biotech Deep Apple.

4.     BMS’ RayzeBio inks prostate cancer radiopharma deal for US$350 million upfront.

5.     XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation®? technology.

6.     Otsuka in-licenses Harbour BioMed’s HBM7020.

Investment

  1. ·      Zynext Ventures Invests in Agenus, fueling expansion of Immuno-Oncology Pipeline and global reach.
  2. ·      Musk's Neuralink raises US$650 million in latest funding as clinical trials begin. According to the company, five patients with severe paralysis are using Neuralink to control digital and physical devices with their thoughts.
  3. ·      Advent International signed a definitive agreement to invest US$175 million in Felix Pharmaceuticals for a significant minority stake.
  4. ·      Oxcia enters a research collaboration with LEO Pharma.

 

Co-development

1.     Alvotech and Dr. Reddy’s Laboratories have entered into an agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab).

2.     In a co-development deal, Bristol Myers to pay US$1.5 billion upfront for BioNTech cancer drug BNT327, for multiple solid tumor types.

3.     NextCure signs up to US$745 million deal with China's Simcere to develop cancer drug.

 

Aagami Updates:

1.     Aagami has received a new assignment from Japanese client, to help them out-license their patented Topical Lidocaine Patch for the US market (FDA approval expected in Sep 2025).

2.     Success for Client: Aagami secured 7 investments for its California based client with Novel and portable MRI (with AI and robotic-guidance) system for in-office use.

3.     Aagami CEO Dinesh Jain fruitfully concluded participation at the BIO International Convention in Boston (June 16–19), with over 50 one-on-meetings with global decision makers. He also moderated a panel discussion in a BIO-affiliated event.

4.     Aagami Research Team (ART) has prepared a report , highlighting select cross border deals of Indian companies covering Jan 2023 – Mar 2025.

a.     The deals reveal robust activity across acquisitions, investments, licensing, and strategic collaborations, highlighting India’s expanding global footprint.

b.     If you would like to receive a complimentary copy of the report, please contact us.

5.     Aagami to participate in the following partnering conferences:

a.     ASIA BIO Partnering Forum | SEP 09-10, 2025 | Singapore

b.     Bio Japan | OCT 08-10, 2025 | PACIFICO Yokohama

c.     BIO-EUROPE   | NOV 03-05, 2025 | Vienna, Austria

 

Select opportunities available with us:

For Partnering/Licensing/ Co-development:

1.     Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach).  By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.

2.     Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).

  1. Seeking Out-licensing: Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.

4.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.

For Acquisition:

1.    A High Multiple ROI by acquiring clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready).

2.    Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.

3.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics.

4.     Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). Now Leveraging the Latest in AI.

Seeking Investment:

1.     High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US $70 Million raised in current round, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.

  1. Market Ready Nutra portfolio of US client leveraging the latest in AI; Offering stake for up to $25 Million investment, and or regional/global rights.
  2. Seeking Investment: Improving cancer survival using smart targeted drug delivery; Lead asset with Paclitaxel in clinical stage [505(b)(2)].
  3. Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications, seeking $10 Million.

Specialized Services

1.     Specialist CDMO of Oligonucleotides and peptides from Japan for one stop solution to accelerate R&D and Kilo Scale manufacturing. 40+ PhDs, Best in quality, excellent customer service and reasonable cost.

Hope you found the content useful. We welcome your feedback and queries.

×
Twitter